SCHEMBL1145684

SCHEMBL1145684

COc1ccc(Br)cc1CO

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.57
KDM4E B2RXH2 4/20 0.55
KMT2A Q03164 4/20 0.55
ALDH1A1 P00352 4/20 0.55
MEN1 O00255 3/20 0.55
TDP1 Q9NUW8 3/20 0.55
MAPT P10636 2/20 0.55
USP2 O75604 1/20 0.55
GAA P10253 1/20 0.55
THRB P10828 1/20 0.55
ALOX15 P16050 1/20 0.55
CASP1 P29466 1/20 0.55
HTT P42858 1/20 0.55
RECQL P46063 1/20 0.55
BLM P54132 1/20 0.55
HSD17B10 Q99714 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.51
LMNA P02545 2/20 0.49
POLB P06746 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6044488 0.85 KDM4E (0.53) KDM4EKMT2AALDH1A1MEN1TDP1
SCHEMBL30223764 0.84 PYCR1 (0.51) PTGDR2KDM4EKMT2AALDH1A1MEN1
SCHEMBL1427602 0.84 PYCR1 (0.51) PTGDR2KDM4EKMT2AALDH1A1MEN1
SCHEMBL29029436 0.83 PTGDR2 (0.61) PTGDR2KMT2AALDH1A1MEN1TDP1
SCHEMBL14097989 0.83 PTGDR2 (0.49) PTGDR2KDM4EKMT2AALDH1A1MEN1
SCHEMBL12849035 0.82 KDM4E (0.45) PTGDR2KDM4EKMT2AALDH1A1MEN1
SCHEMBL8712221 0.82 PTGDR2 (0.59) PTGDR2KDM4EKMT2AALDH1A1MEN1
SCHEMBL30152364 0.82 PTGDR2 (0.59) PTGDR2KDM4EKMT2AALDH1A1MEN1
SCHEMBL31288205 0.82 KDM4E (0.56) KDM4EKMT2AALDH1A1MEN1TDP1
SCHEMBL1990376 0.82 KDM4E (0.56) KDM4EKMT2AALDH1A1MEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6989052-B1 Phase change ink printing process XEROX CORPORATION (US) 2006-01-24 US claimed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 US claimed
US-6495243-B1 Recording substrates for ink jet printing XEROX CORPORATION 2002-12-17 US claimed
US-5759734-A Method of generating simulated photographic-quality images on luminescent melt-formed backing substrates XEROX CORPORATION (US) 1998-06-02 US claimed
US-12559504-B2 Benzotriazole derivative UBE CORPORATION (JP) 2026-02-24 US disclosed
EP-3978073-B1 1H-BENZO[D][1,2,3]TRIAZOLE DERIVATIVES AS KEAP1 INHIBITORS FOR THE TREATMENT OF RENAL DISEASES UBE CORP (JP) 2025-10-15 EP disclosed
CN-114174289-B Benzotriazole derivatives UBE株式会社 2025-03-07 CN disclosed
CN-112969682-B Compound, resin precursor, cured product, optical element, and optical system 株式会社尼康 2023-09-26 CN disclosed
US-20230097678-A1 NEW MACROCYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2023-03-30 US disclosed
CN-112920130-B Triazole compound, preparation method and application thereof in preparation of cancer prevention and treatment drugs 河北康泰药业有限公司 2023-03-17 CN disclosed
EP-4110776-A1 NEW MACROCYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Les Laboratoires Servier (FR) 2023-01-04 EP disclosed
US-20220411377-A1 SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS NORTHWESTERN UNIVERSITY 2022-12-29 US disclosed
EP-1048666-A1 NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-11-02 EP disclosed
US-6110934-A Substituted benzamide derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. (GB) 2000-08-29 US disclosed
EP-1025087-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2000-08-09 EP disclosed
WO-1999052857-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 1999-10-21 WO disclosed
WO-1999021836-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1999-05-06 WO disclosed
EP-0906283-A1 SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1999-04-07 EP disclosed
US-5759734-A Method of generating simulated photographic-quality images on luminescent melt-formed backing substrates XEROX CORPORATION (US) 1998-06-02 US disclosed
WO-1997048683-A1 SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1997-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411377-A1 SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS NOS3, NOS1, NOS2 PTGDR2 793/4885KDM4E 3093/4885KMT2A 3078/4885
US-12559504-B2 Benzotriazole derivative KEAP1, NFE2L2, NCOR1 PTGDR2 2194/4885KDM4E 502/4885KMT2A 347/4885
US-20230097678-A1 NEW MACROCYCLIC COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM C1S, C1R, F12 PTGDR2 852/4885KDM4E 4031/4885KMT2A 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.